Pilatus Biosciences Secures U.S. Patent Allowance and Worldwide IP Rights for CD36-Targeted Cancer Therapy PLT012
核心洞察
Pilatus Biosciences (搜索) received a Notice of Allowance from the USPTO for U.S. Patent Application No. 18/844,588 covering its lead anti-CD36 (搜索) monoclonal antibody, PLT012.
The company completed acquisition of worldwide rights to the patent family derived from PCT/US2023/063766, giving it direct ownership and control of key IP.
PLT012 is a first-in-class CD36 (搜索)-targeted therapy designed to block lipid uptake and reprogram the tumor microenvironment to restore antitumor immunity.
Pilatus Biosciences (搜索), a biopharmaceutical company developing novel metabolic checkpoint immunotherapies for cancer, has announced two intellectual property milestones for PLT012, its lead investigational anti-CD36 (搜索) monoclonal antibody: receipt of a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application No. 18/844,588, and completion of the acquisition of worldwide rights to the related patent family derived from PCT/US2023/063766.
The patent family, titled "Anti-CD36 (搜索) Antibodies and Uses Thereof," relates to anti-CD36 antibodies including PLT012 and their therapeutic applications. It describes antibodies designed to bind to human CD36 with high affinity and inhibit CD36-mediated biological functions, including fatty acid transport and associated immune-regulatory effects.
These achievements followed the Company's previously announced dosing of the first patient in the United States and completion of the associated development efforts. Together, the milestones give Pilatus direct ownership and control of the worldwide patent family, enabling the Company to manage its prosecution, maintain and enforce these patent rights as it advances the program in connection with potential future development, partnering and other strategic opportunities.
"These developments mark an important step in strengthening the IP foundation for PLT012 as we continue to advance the program," said Raven Lin, Ph.D., Co-Founder and Chief Executive Officer, Pilatus Biosciences (搜索). "Following our first-patient-dosing milestone in the United States, we have consolidated ownership of the worldwide patent family supporting PLT012 and secured a Notice of Allowance for a key U.S. patent application. These milestones further strengthen our IP position around our lead program and our ability to protect and advance PLT012 through clinical development while pursuing future development and strategic opportunities."
Mechanism of Action and Clinical Rationale
PLT012 is designed to block CD36 (搜索)-mediated lipid uptake, a mechanism implicated in metabolic dysfunction and immune suppression within the tumor microenvironment (TME). By inhibiting this pathway, Pilatus aims to restore antitumor immune activity via TME reprogramming.
PLT012 is described as a first-in-class therapeutic targeting CD36 (搜索), a key regulator of metabolic dysfunction and inflammation. The program is being developed for indications where modulation of CD36 has the potential to improve patient outcomes.
Complementary IP Portfolio
These developments build on Pilatus' expanding IP portfolio around CD36 (搜索). In October 2025, the Company announced the grant of foundational patents in Europe and Australia from a separate patent family exclusively licensed to Pilatus from the Ludwig Institute for Cancer Research and the University of Lausanne, covering the modulation of regulatory T cells and inhibition of tumor growth through CD36 targeting.
This exclusively licensed patent family, and the newly acquired worldwide patent family directly owned by Pilatus, provide complementary layers of IP protection around Pilatus' CD36 (搜索)-targeted approach and PLT012 as the Company advances its broader metabolic checkpoint platform.
Clinical Development Progress
Pilatus Biosciences (搜索), which develops metabolic checkpoint immunotherapies for liver and gastrointestinal cancers, has received the Certificate for Clinical Trial / Medicinal Test from the Hong Kong Department of Health for PLT012 in patients with advanced solid tumors (搜索). The company has also established a Hong Kong subsidiary.
The study will be conducted at the Phase I Clinical Trial Centre, under the Department of Clinical Oncology of The Chinese University of Hong Kong, with Dr. Stephen Chan as principal investigator. The new subsidiary expands the company's presence in one of Asia's leading biotechnology and clinical-research hubs, where Pilatus plans to draw on the territory's life sciences ecosystem to support clinical development, academic and strategic collaborations, and engagement with regional investors.